Podcasts about Moderna

O absolutismo costuma ser apresentado como um sistema em que os reis concentravam poder ilimitado e governavam sem qualquer restrição. No entanto, essa definição não só está longe de ser consensual entre os historiadores, como é cada vez mais rechaçada por estes profissionais. Nas últimas décadas, diversas pesquisas têm questionado a própria utilidade do conceito, mostrando que os monarcas da Época Moderna precisavam negociar constantemente com nobres, parlamentos, cortes de justiça, instituições religiosas e autoridades locais para exercer seu poder. Ao mesmo tempo, a imagem de soberanos capazes de controlar todos os aspectos da vida política muitas vezes resulta mais de interpretações posteriores do que da realidade histórica. Debater o absolutismo, portanto, significa também discutir como os conceitos históricos são construídos, revisados e reinterpretados à luz de novas evidências e perspectivas historiográficas. Convidamos Daniel Gomes de Carvalho para analisar as diferentes interpretações sobre o absolutismo, discutir os limites do poder das monarquias da Época Moderna, explicar por que esse conceito continua sendo objeto de debate entre os historiadores e refletir sobre como a historiografia tem revisado as concepções tradicionais a respeito desse tema.Roteiro: Icles RodriguesEdição: Samuel GambiniInstagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@iclesrodrigues⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PIX: leituraobrigahistoria@gmail.comAdquira o curso História: da pesquisa à escrita por apenas R$ 49,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso A Operação Historiográfica para Michel de Certeau por apenas R$ 24,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso O ofício do historiador para Marc Bloch por apenas R$ 29,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Colabore com nosso trabalho em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/obrigahistoria⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dia dos pais Insider! compras do dia 5 de agosto têm 10% de desconto no pix e frete grátis a partir de 399 reais em compras. Do dia 6 ao 8, brindes cumulativos como meias, cuecas ou calcinhas, e boné ou sutiã, a depender do valor da compra. Use meu cupom HISTORIAFM ou acesse o site pelo link ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.insiderstore.com.br/HISTORIAFM⁠⁠⁠⁠⁠⁠⁠⁠⁠ e aproveite! #insiderstore

La Amazonía es la selva tropical más grande del mundo, hogar de cientos de pueblos indígenas que han conservado una gran sabiduría ancestral con la naturaleza, conocimientos que ha adquirido la doctora Rosa Vásquez durante años de experiencia, aprendiendo de la perspectiva indígena donde se reconoce que la naturaleza está viva y cuidarla es cuidar de nosotros mismos.Consulta la información completa en: peninsula360press.com

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Acceso anticipado para Fans - ** VIDEO EN NUESTRO CANAL DE YOUTUBE **** https://youtube.com/live/AVrK0EoFljA +++++ Hazte con nuestras camisetas en https://www.bhmshop.app +++++ En este programa de Bellumartis Historia Militar y Geopolítica hablamos con el historiador Javier Barraycoa sobre su libro “El genocidio de la Vendée y la primera cruzada moderna” ** https://amzn.to/3PTP1v8 ** La Revolución Francesa no trajo solo libertad. Para cientos de miles de personas trajo el exterminio. En 1793, campesinos sencillos de la Vendée, armados con hoces y rosarios, se enfrentaron a las Columnas Infernales de la Convención. Luchaban por su fe, sus sacerdotes y su forma de vida. Pagaron ese coraje con lo que muchos historiadores consideran el primer genocidio de la era moderna. Javier Barraycoa rescata esta historia silenciada durante dos siglos, los héroes olvidados como Cathelineau y La Rochejaquelein, y denuncia el memoricidio posterior: el silencio impuesto, la tesis de Reynald Secher y el relato oficial que durante generaciones prefirió olvidar. Un análisis riguroso, documentado y valiente que desmonta uno de los mitos más sagrados de la modernidad occidental. Si te interesa la historia militar sin filtros, la geopolítica y un enfoque honesto de nuestra tradición occidental, este programa es para ti. Dale like si quieres más contenido riguroso como este Suscríbete y activa la campana para no perderte los próximos programas Comenta: ¿Conocías la historia de la Vendée? ¿Crees que fue un genocidio? #GenocidioVendée #JavierBarraycoa #RevoluciónFrancesa #HistoriaMilitar #Vendée #ColumnasInfernales #PrimeraCruzadaModerna #BellumartisEscucha este episodio completo y accede a todo el contenido exclusivo de BELLUMARTIS PODCAST. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/618669

Send us Fan MailWhat if I told you there is a major genetic risk factor for heart attacks and strokes that affects roughly one in five people worldwide - but most people have never heard of it, and it isn't measured on a standard cholesterol test? Today we're exploring Lp(a), the hidden cardiovascular risk factor that could reshape the future of heart disease prevention.Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P., is Senior Vice President and Chief Medical Officer of Amgen ( https://www.amgen.com/about/leadership/senior-management/paul-burton ).Dr. Burton has built one of the most remarkable careers in modern medicine and biotechnology. After training as a physician and cardiovascular surgeon in the United Kingdom and earning a Ph.D. in molecular and cellular biology from Imperial College London, he transitioned into the biotechnology industry, where he has spent more than two decades leading the development of innovative medicines across cardiovascular disease, oncology, infectious disease, metabolic disorders and RNA therapeutics.Before returning to Amgen as Chief Medical Officer in 2023, Dr. Burton served as Chief Medical Officer of Moderna during one of the most consequential periods in modern public health, overseeing global medical strategy and pharmacovigilance. Prior to that he spent sixteen years at Johnson & Johnson, ultimately serving as Chief Global Medical Affairs Officer while helping pioneer digital medicine initiatives, including collaborations exploring virtual clinical trials.Today, Dr. Burton leads Amgen's worldwide medical organization, helping guide one of the industry's broadest research pipelines while translating breakthrough science into therapies that can improve - and potentially save - millions of lives.One of those efforts is Amgen's ambitious work targeting lipoprotein(a), or Lp(a), a genetically inherited cardiovascular risk factor affecting roughly one in five people worldwide. Through its investigational siRNA therapy olpasiran and the expansive OCEAN(a) clinical program, Amgen hopes to answer one of the biggest remaining questions in preventive cardiology: can dramatically lowering Lp(a) prevent heart attacks and strokes?Today we'll explore Dr. Burton's fascinating career, what it means to lead medical strategy at one of biotechnology's largest innovators, and why the next decade may fundamentally reshape how we prevent cardiovascular disease.#Cardiology #HeartDisease #LpA #LipoproteinA #PrecisionMedicine #RNAmedicine #GeneSilencing #Biotechnology #Biotech #Amgen #DrugDiscovery #PharmaceuticalInnovation #FutureOfMedicine #CardiovascularHealth #HeartHealth #MedicalInnovation #HealthcareInnovation #PreventiveMedicine #Genomics #SiRNA #LongevityScience #RegenerativeMedicine #ClinicalTrials #Pharma #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- 100 errores de mentalidad liderazgo y gestión, que limitan el crecimiento de las empresas Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Hacemos balance de los resultados empresariales de Wall Street, con vistazo a Boeing, ExxonMobil y Moderna. Con Rafael Ojeda, miembro del Comité de Inversiones de Ursus 3 Capital.

"We have an untapped army of 200,000 PAs that really could step up and drive some change in the healthcare system if we weren't restricted,” says Dr. Jennifer Kolb, capturing her motivation for pushing to update practice regulations for physician associates that date back more than 50 years.  As Chief Medical Officer and Senior Vice President of Clinical Affairs at the American Academy of Physician Associates, Dr. Kolb has been in the middle of the fight at the state and federal level to grant PAs more independence from physicians, full billing rights, and the increased ability to practice across state lines, among other changes.  In this pertinent conversation with Raise the Line host Lindsey Smith, Dr. Kolb explains how these updates could help close huge gaps in access to healthcare, better manage the fight against chronic diseases and improve patient outcomes.   Dr. Kolb also addresses:  Why the name shift from "assistant" to "associate" took her years to fully appreciate; How a 10-year gap in life expectancy across Chicago zip codes shapes her view of health equity; Why PA's shouldn't wait for permission to start making change in their communities. Mentioned in this episode:American Academy of Physician Associates   If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Muchas personas, y cada día más, sufren de soledad pero no lo han identificado o no saben cómo salirse de ese circulo vicioso al que nos lleva la vida moderna actual. Cuando el mundo se media cada día más por pantallas, viviendas aisladas y vida automatizada, aparecen problemas que no presupuestabamos y la soledad es uno de ellos. Hoy hablaremos de este tema tan importante y te daré algunas ideas de cómo contrarestar esa sensación si sientes que está presente en tu vida. ¡Espero te inspire!

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- Masajes Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Most adults who smoke want to quit, and about half try to do so in any given year, yet fewer than one in ten succeed. That persistent gap between intention and outcome is one of the central challenges in public health, and it's exactly the kind of problem that calls for new thinking about how to communicate with people to support behavior change.  Dr. Amanda Graham has been a leading force in doing just that in her role as chief health officer at Truth Initiative, the nation's largest non-profit public health organization dedicated to preventing addiction among young people and helping people of all ages to quit tobacco. On this episode of Raise the Line from Elsevier, Dr. Graham, who holds a PhD in clinical health psychology and has done 25 years of NIH-funded research focused on technology-based cessation interventions, helps us understand the interplay between behavioral science and digital communications in the field. "A well-timed message can really be powerful in interrupting what for many people is kind of an automatic behavior, especially via text, which data tell us is an extraordinarily powerful modality,” she explains to host Lindsey Smith.  Tune-in to understand where the field is heading, and to learn about: Why "push" technology may work better than apps and websites when it comes to breaking automatic behaviors; How the rise of e-cigarettes, nicotine pouches, and heated tobacco has scrambled decades of public health messaging; How highschool smoking rates plunged from over 30% to less than 2%. Mentioned in this episode: Truth Initiative Program with Mayo Clinic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

────────────────────────────────────────[00:02:23]Moderna Launching an mRNA Cancer Vaccine — for Patients Who Already Have Metastatic CancerThe shot caused the cancer explosion; now programming immune-compromised patients to produce tumor proteins; control group gets a different mRNA — no placebo.────────────────────────────────────────[00:10:05]Scientists Warn Moderna's mRNA Cancer Vaccine May Itself Cause Tumor GrowthJessica Rose: undisclosed antigens prevent independent safety assessment; Dr. Hoecker: counterintuitive to promote a therapy that causes cancer; FDA will approve it anyway.────────────────────────────────────────[00:34:38]Whistleblower Doctor: Booster Interval Timed to Hit White Blood Cell Production While DownFirst dose cuts production by 50%; second drops it to 25%; booster carries 81 strands of foreign bacteria the weakened immune system cannot fight.────────────────────────────────────────[00:38:48]Acosta Gave Epstein a Sweetheart Deal Because He Was Told Epstein Was Intelligence — Ken Starr Then Became His Defense AttorneyThe same Starr who gave Clinton a pass became Epstein's lawyer; a victim who refused to speak was forced forward when DOJ published her name.────────────────────────────────────────[00:40:32]Trump Sent Ivanka as a Teenager to Brunel — Modeling Agent Later Convicted of Rape and PedophiliaBrunel trafficked women into debt bondage for Epstein; the Uzbek woman now speaking out was one of his victims; Brunel died in prison in 2022.────────────────────────────────────────[01:14:55]China Cut Oil Consumption to Prevent a Global Depression — Trump Appears to Be Trying to Create OneChinese foreign minister: the Strait was open before the war; US-Israel operations created the crisis; China offset 5% of the 20% lost by cutting its consumption.────────────────────────────────────────[01:21:11]After the Iran War, Both Sides Have Revealed Their Limits — Next Conflict Requires a Domestic TriggerUS and Israel cannot change Tehran by force; Iran cannot inflict critical damage; both will prepare for a conflict requiring something to happen on American soil.────────────────────────────────────────[01:25:07]Hegseth Asks Congress for $1.5 Trillion for a War Trump Already Declared WonSenator to Hegseth: unlimited bomb money while cutting food, healthcare, and farm support; Palmer Luckey is building autonomous Terminator drones with Thiel's money.────────────────────────────────────────[01:52:30]The Covenant With Moses Was Conditional — Israel Broke It and God Destroyed the Nation ForeverPalestine today is a devilish counterfeit; the Old Testament testifies of Christ, not an ethnic group or political state — fundamental error of Christian Zionism.────────────────────────────────────────[01:55:08]Trump Contradicts Himself in the Same Sentence — Desperate to Meet Iran, But Not ReadyIran's missiles change speed mid-flight defeating every US defense system; Trump blamed Jordan attack on Jordanians. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:02:23]Moderna Launching an mRNA Cancer Vaccine — for Patients Who Already Have Metastatic CancerThe shot caused the cancer explosion; now programming immune-compromised patients to produce tumor proteins; control group gets a different mRNA — no placebo.────────────────────────────────────────[00:10:05]Scientists Warn Moderna's mRNA Cancer Vaccine May Itself Cause Tumor GrowthJessica Rose: undisclosed antigens prevent independent safety assessment; Dr. Hoecker: counterintuitive to promote a therapy that causes cancer; FDA will approve it anyway.────────────────────────────────────────[00:34:38]Whistleblower Doctor: Booster Interval Timed to Hit White Blood Cell Production While DownFirst dose cuts production by 50%; second drops it to 25%; booster carries 81 strands of foreign bacteria the weakened immune system cannot fight.────────────────────────────────────────[00:38:48]Acosta Gave Epstein a Sweetheart Deal Because He Was Told Epstein Was Intelligence — Ken Starr Then Became His Defense AttorneyThe same Starr who gave Clinton a pass became Epstein's lawyer; a victim who refused to speak was forced forward when DOJ published her name.────────────────────────────────────────[00:40:32]Trump Sent Ivanka as a Teenager to Brunel — Modeling Agent Later Convicted of Rape and PedophiliaBrunel trafficked women into debt bondage for Epstein; the Uzbek woman now speaking out was one of his victims; Brunel died in prison in 2022.────────────────────────────────────────[01:14:55]China Cut Oil Consumption to Prevent a Global Depression — Trump Appears to Be Trying to Create OneChinese foreign minister: the Strait was open before the war; US-Israel operations created the crisis; China offset 5% of the 20% lost by cutting its consumption.────────────────────────────────────────[01:21:11]After the Iran War, Both Sides Have Revealed Their Limits — Next Conflict Requires a Domestic TriggerUS and Israel cannot change Tehran by force; Iran cannot inflict critical damage; both will prepare for a conflict requiring something to happen on American soil.────────────────────────────────────────[01:25:07]Hegseth Asks Congress for $1.5 Trillion for a War Trump Already Declared WonSenator to Hegseth: unlimited bomb money while cutting food, healthcare, and farm support; Palmer Luckey is building autonomous Terminator drones with Thiel's money.────────────────────────────────────────[01:52:30]The Covenant With Moses Was Conditional — Israel Broke It and God Destroyed the Nation ForeverPalestine today is a devilish counterfeit; the Old Testament testifies of Christ, not an ethnic group or political state — fundamental error of Christian Zionism.────────────────────────────────────────[01:55:08]Trump Contradicts Himself in the Same Sentence — Desperate to Meet Iran, But Not ReadyIran's missiles change speed mid-flight defeating every US defense system; Trump blamed Jordan attack on Jordanians. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Episode 2860 - In this episode, Ted and Austin Broer connect Moderna's RNA cancer shot trial dangers, COVID vaccine memory issues and hospital whistleblower claims, acai berry antioxidant benefits, Berberine's blood sugar and body fat management superiority, the trades career opportunity versus student loan default crisis, EV market collapse and hybrid technology promise, and the Andrew and Tate arrest for dating scams into a broadcast that delivers both urgent health warnings and sharp economic and cultural commentary.

Why Your Stroke May Not Be Causing Your Brain Fatigue For a long time after my brain surgery, I assumed my body worked like this: the stroke happened in my head, so whatever went wrong afterward would also happen in my head. Fatigue, brain fog, slow thinking all of it filed under “neurological,” all of it explained by the injury I already knew about. That assumption turned out to be wrong, and the way I found out was almost accidental. About eighteen months after my brain surgery, I had thyroid surgery to remove a nodule so large it had pushed my windpipe and esophagus six centimeters out of place. I had no idea it was there. No lump I could see, no difficulty swallowing or breathing that I’d noticed. It was found only because I had a chest X-ray to rule out an infection, and a doctor spotted something that had nothing to do with why I’d walked in. What followed was a slow, confusing recovery from that second surgery, and a wave of fatigue I automatically blamed on my brain, because that was the injury I already understood. It took time to realize the fatigue might be coming from somewhere else entirely: my thyroid. Hormones and Stroke Recovery: The Connection Nobody Talks About I brought this experience to Dr. Robert Hedaya, a Clinical Professor of Psychiatry at Georgetown University Medical Center and a pioneer of functional medicine psychiatry, to understand what actually happened, and to ask a bigger question: how many other stroke survivors are dealing with fatigue, brain fog, or mood changes that they’ve written off as “just the stroke,” when the real driver is a hormonal system that’s quietly stopped working properly? Hormones and stroke recovery turn out to be far more entangled than most of us are told. As Dr. Hedaya put it plainly: the brain is a hormonal organ. Thyroid hormone, cortisol, testosterone, estrogen every one of them acts directly on brain tissue, and every one of them can be knocked off balance by the stress of a major medical event. Why “Normal” Thyroid Bloodwork Can Still Mean Something’s Wrong One of the most important things Dr. Hedaya explained is that a “normal” TSH result doesn’t rule out a thyroid problem, especially after a stroke. TSH is a signal sent from the pituitary gland, and if a stroke has affected the brain’s signaling pathways, the pituitary itself may not respond the way it should. A survivor can have genuinely low thyroid hormone while their TSH sits comfortably inside the standard reference range, because the system responsible for raising that number in response to a deficiency isn’t functioning correctly. He also raised a striking data point: population studies suggest the average TSH in a healthy population is closer to 1.4, yet most labs still use an upper reference limit of 4.5, a range wide enough, statistically, to miss a real problem. His advice for survivors going into a GP appointment: ask specifically for TSH, free T4, free T3, and reverse T3, not just the standard single-marker test, and come prepared with symptoms written down if a doctor pushes back. A Nodule That Grew in Silence The brain is a hormonal organ. It’s an immune organ. It’s a neurological organ… there’s not one hormonal axis when it’s abnormal that cannot cause neurological or psychiatric problems. -Dr. Robert Hedaya My own nodule is a case study in exactly this kind of silent progression. Dr. Hedaya explained that because it grew inward rather than outward, it never created the visible lump most people associate with a thyroid problem, and because it didn’t press on my vocal cords or laryngeal nerve, I never developed the hoarseness that might have flagged it sooner. My body adapted gradually, and the fatigue that eventually surfaced was easy to misattribute to the injury I already knew I had. Cortisol, Stress, and the Difference Between Pain and Suffering Beyond the thyroid, Dr. Hedaya walked through the role of cortisol, the body’s primary stress hormone, and why survivors often struggle to answer a deceptively simple question: “Are you stressed?” His distinction between pain and suffering is worth sitting with: pain is often unavoidable, but suffering is shaped by the story we tell ourselves about a situation, and a stroke can compromise the very brain systems that regulate that stress response in the first place. Testosterone, Estrogen, and the Brain’s Need for Hormones to Rewire The conversation closed on sex hormones, testosterone and estrogen, relevant to both men and women, and their role in neuroplasticity. Dr. Hedaya drew a direct comparison to adolescence: the teenage brain rewires itself while hormone levels are surging, and the same principle applies after a stroke. A brain trying to rebuild pathways needs adequate hormonal support to do that work. Without it, recovery can stall in ways that have nothing to do with effort or physiotherapy. What You Can Do About It If any of this sounds familiar fatigue that doesn’t track cleanly with other recovery milestones, or symptoms a doctor has waved off as “just stress,” Dr. Hedaya’s PNIE (psycho-neuro-immuno-endocrinology) questionnaire is a useful starting point. PNIE Questionnaire download: https://drive.google.com/file/d/1S7kC5uMFgBfS-gWcUOIHp0kOjGnrzZK5/view?usp=sharing If thyroid function specifically is what you’re navigating, the earlier conversation with Dr. Elena Zinkov, “Stroke Fatigue and Thyroid,” goes deeper into that piece (https://recoveryafterstroke.com/stroke-fatigue-and-thyroid/). And for more from Dr. Hedaya, the first conversation on photobiomodulation and stroke recovery is a good companion listen (https://recoveryafterstroke.com/photobiomodulation-stroke-recovery/). Getting your body back after a stroke is rarely just about the brain. My book, The Unexpected Way That A Stroke Became The Best Thing That Happened, goes further into the mindset shifts that came out of my own recovery (recoveryafterstroke.com/book). And if this podcast has helped you, you can support its continuation at patreon.com/recoveryafterstroke. This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. Hormones, Fatigue, and the Brain: Dr. Robert Hedaya Returns (Interview) A baseball-sized thyroid nodule hid in plain sight after Bill’s stroke. Dr. Hedaya explains the hormone testing every survivor should ask for. Support The Recovery After Stroke Podcast Bill’s Book: The Unexpected Way That a Stroke Became Thethe Best Thing That Happened Highlights: 01:45 Hormones and Stroke Recovery 02:11 Understanding Thyroid Function and Its Impact 17:07 Navigating Thyroid Health with Healthcare Providers 27:09 The Role of Stress and Cortisol 39:09 Nutrition’s Impact on Brain Recovery Transcript: Hormones and Stroke Recovery Bill Gasiamis (00:00) And they noticed a massive lump in my throat and my esophagus and my windpipe were pushed six centimeters. And they said to me, well, can you swallow? Can you breathe? Can you do it? And I was like, yeah, I’m all fine. There’s nothing wrong with my throat. that was the first sign that there was something wrong with my thyroid Bill Gasiamis (00:19) Welcome back to Recovery After Stroke. I’m Bill Garciamas, and today I’m joined again by Dr. Robert Hedeya, clinical professor of psychiatry at Georgetown University Medical Center and a pioneer of functional medicine psychiatry, whose highland approach to brain health first brought him onto the show for our conversation on episode 404, where we discussed, amongst other things, photobiomodulation, a type of transcript. cranial laser therapy helping some stroke survivors recover lost function. He’s back today for a conversation I wanted to have for a while, the hormonal side of stroke recovery. We’re going to talk about thyroid function, cortisol, and stress physiology, and sex hormones like testosterone and estrogen, and why every one of these systems can directly affect how well and how fast your brain recovers. I’ll also share my own story of a thyroid nodule that grew undetected, which was discovered after my brain surgery completely by accident. if this conversation resonates with you, my book, The Unexpected Way That a Stroke Became Thethe Best Thing That Happened goes deeper into the mindset shifts that shaped my own recovery. You can find it at recoveryafterstroke.com/book. And if you’d like to help keep this podcast going, you can support it financially at patreon.com/recoveryafterstroke. Bill Gasiamis (01:46) Robert Hedaya, welcome back to the podcast. Dr Hedaya (01:49) Thank you for having me, Bill. Understanding Thyroid Function and Its Impact Bill Gasiamis (01:51) thank you for being here. The last conversation we had was very well received. And it’s always difficult in a one hour interview to ask all the questions that we could possibly ask about the brain and stroke recovery and all the things that people go through. And… I’ve got a lot of other questions that are related to the brain and the link between other parts of the body and the brain, because we have this sense. Well, I did at least when I was first diagnosed that whatever happens in my head is kind of isolated, that it just impacts my head. But there seemed to be some other impacts and cascading effects. that were occurring, uh, that I didn’t know were linked to the brain injury, Dr Hedaya (02:45) Yeah. Bill Gasiamis (02:46) maybe indirectly, but they were perhaps. But one thing specifically that happened to me about, uh, 18 months after my brain surgery was I had thyroid surgery to remove a nodule on my thyroid. And when I was going through the recovery after that, surgery, I noticed that I had fatigue and I thought it was neurological fatigue related to my brain surgery. But it took a long time to develop an understanding that perhaps that batch of fatigue was related to my thyroid. And then that got me thinking all sorts of things. know, if the thyroid also causes the same neurological fatigue that brain injury causes, what people might be missing this in their healing from a brain injury, they might have a compromised thyroid and not know about it. So the first question is, what is a thyroid? What does it do? And why does it cause neurological fatigue? Dr Hedaya (03:54) Okay. So thyroid gland sits in the neck, right? There’s two lobes, there’s one on the right, one on the left, a little kind of island in the middle called the isthmus, and and it controls many functions, metabolism overall, energy overall, just broadly speaking. now it affects the immune system. It’s affects the nervous system. It affects the gastrointestinal system, it affects the muscles, it affects the heart, right? It affects the skin, it affects the nails, it affects the hair. You know, and I could go on and on and on. Okay? Bill Gasiamis (04:34) Wow. Dr Hedaya (04:35) Now the interesting thing about this is that this be a little technical, but the thyroid puts out a hormone called T4 or thyroxine, and this is a little molecule with four iodines in it on it, and that Gives you about 20% of the activity of your thyroid hormones in your body. But then that T4 goes all over the body to different tissues, and each tissue can has its own system to change that T4 into T3 by removing an iodine. T3 has 80% of the thyroid activity. So that means each tissue in the body can control how much thyroid it. It’s using and needs, right? And and has available to it. Okay. So that means the brain, the heart, the liver, the lungs, every tissue has its own enzyme that allows it to kind of modulate how much thyroid, right? Now, so why does that cause neurological fatigue? Well, thyroid in the brain affects neurotransmitters like adrenaline in the brain, which is called nor norepinephrine, noradrenaline. in order for that to work. The T3 has to be in the right amount for the receptors for the noradrenaline to be structurally correct so they can transmit the signal. It’s necessary for production of energy in all the brain cells. It helps the immune system in the brain. It carries molecules from here to there in the brain. it affects serotonin transmission in the brain, so mood regulation, anxiety, obsessiveness, depression. You know, those are just some of the functions of the brain, but it affects every cell in the bane in the brain. So you’re gonna, if your thyroid is off, most likely you’re gonna have some kind of brain problems, particularly, you know, when your thyroid is off, the tissues in your body that are most compromised or most stressed, that’s probably where it’s gonna show up, right? And in the case of stroke, that’s where it’ll show up. Bill Gasiamis (06:44) So it’s possible then, is it possible to overlook it? Is it very obvious that your thyroid is out of, well, is dysregulated or is not working properly? Dr Hedaya (06:56) Well, in general it’s easy to detect. And if you want, I’ll tell you how. So Bill Gasiamis (07:04) Yeah. Tell me how. Dr Hedaya (07:07) so there’s some blood tests that are simple and then s some symptoms. so for most people this holds. When your thyroid is low, you know, you’re gonna be cold easily, you’re gonna have dry skin, brittle nails, hair will fall out. Muscles will be weak, thinking will be slow, movement will be slow, getting up from a chair will be more difficult, going upstairs will be more difficult, your heart rate will slow down, you’ll be constipated. Those are the most common symptoms. If your thyroid is overactive, then you could be have palpitations, oily skin, acne, oily hair. Diarrhea, you know, kind of the opposite. The thing that’s a little confusing with the thyroid is sometimes overactive thyroid can show up and look like it’s underactive symptomatically, or vice versa. So you really need the labs. And the labs are TSH, which is thyroid stimulating hormone, and that’s tells you what the brain is doing. And then free T4. That’s the amount of T4 that’s kind of floating around free, not bound to protein, so it can actually do its job. The way I think of it is like, you know, a lot of the thyroid home is sitting on a bus. It’s not free, it’s bound to protein. Can’t do its job. But the stuff the thyroid this that’s out of the bus or not on a protein, that can do its job. That’s the free T four. And then the free T three, right, which carries eighty percent of thyroid activity. And then the last one is a reverse T3 because sometimes if your tissues in your body are making too much thyroid or getting too much thyroid, they’ll actually, instead of taking the iodine off the T4 molecule on the right side, they’ll take it off on the left side, or vice versa. So they make a fake T3 that doesn’t work. And this way they short circuited okay, you got all this T3. Well, let’s make it into a fake, fake T3 so it can’t do anything. So reverse T3 is also very important. And then you want to measure body temperature. Usually it’ll be low. And then, you know, a physical exam. Those are the ways to do it. If you wanted to go even deeper, you could do some genetic testing. There are genes that will tell you whether you’re converting the T4 to T3 in the brain. Adequately, or maybe you’re more likely to be slow in that regard. So you can have normal numbers in your blood, but your brain might be hypothyroid, right? And there are actually a lot Bill Gasiamis (10:05) Uh-huh. Dr Hedaya (10:05) of studies showing that hypermetabolic, like high doses of free T3, actually reverse treatment-resistant depression because it’s it’s thought that there’s a local in-brain. hypo-low thyroidism. You can have low thyroidism in your heart, in your muscles, but not in the other tissues, you know, because I told you every tissue can control how much it’s making. So if you have a genetic vulnerability, then you you might more be in general be more likely vulnerable to depression or to ADD or to anxiety, things like that. Bill Gasiamis (10:42) Wow. Are you blowing me away? I didn’t expect to hear any of the things that you just said. X. Um, some of the things that you described, the, uh, some of the symptoms that you described, had those intermittently in and out all the time, other than a thyroid nodule, which is what I had, which was obvious on a scan. Dr Hedaya (11:05) Yeah. Bill Gasiamis (11:06) What other things caused the thyroid to not function? correctly. So is there lifestyle factors that interfere with the thyroid gland and therefore, you know, then have the cascading effect and take off, take all those other things or some of those other things offline. Dr Hedaya (11:28) So there a number of causes, right? So first of all, let’s take someone who has had a stroke or chronic illness, right? So you’re under stress and that affects your stress hormones, your adrenal glands, cortisol, etc. Well, if your adrenals kind of poop out, then maybe your body says, Well, I can’t handle all this thyroid, even though the amount is normal, it’s like too much. I can’t handle it, so it’ll make less thyroids. Now you develop a hypothyroidism. You could develop it just because all the chemicals in the environment, the ha the hormone interrupting chemicals, there are hundreds of those. you could develop it ’cause of nutritional deficiencies like tyrosine is necessary to make thyroid hormone, copper, you know, things like that. I can’t tell you offhand which which nutritional factors, but people can look that up, what nutritional factors are important. To make thyroid hormone. and then infections like, for example, Lyme disease causes Hashimoto’s thyroiditis, which is an autoimmune where your immune system’s actually attacking your thyroid. COVID vaccination, like the Pfizer and the Moderna vaccine, if you are genetically vulnerable, can also cause your immune system to attack your thyroid. So there are many, many causes, plus there are inherited genetic vulnerabilities and it It’s not always low thyroid, sometimes it’s high thyroid, hyperthyroidism, like Graves’ disease, right? You can have antibodies Bill Gasiamis (13:01) Mm-hmm. Dr Hedaya (13:02) that are actually stimulating thyroid activity as well. Bill Gasiamis (13:06) Wow. The environmental toxins. we talking about all day, every day household use kind of environmental toxins? I imagine the external of the house, they’re kind of out of our control, right? We’ll talk about like, you know, like pollution or things that are associated to things that are caused that we don’t necessarily control, but internally inside the house or what we expose ourselves to that we can control. what would some of those environmental toxins Dr Hedaya (13:38) Well Bill Gasiamis (13:39) be? Dr Hedaya (13:40) so for example, you know, in your produce, you know, there are pesticides, or in the man made materials in your car or the man made materials in your home. Let’s say you bought a new home and you have, you know, some kind of synthetic floors or furniture with synthetic materials or materials that are natural that are treated with chemicals for various reasons. Those things all can be not everyone is, but many of them are called homes. hormone interruptors because they actually can change the way your hormones function. You know? So we’re the truth is we’re bathed in these chemicals. They’re everywhere. And very hard to escape them. The best thing you can do is kind of try to detox them using a healthy diet, a lot of crucifer vegetables and lots of vegetables, above ground vegetables that are grown in healthy soil. Without pesticides, organic preferably, right? and then there are supplements you can take, such as metagenics makes something called UltraClear Plus, which helps support the liver, and its detox functions. You know, some people are more vulnerable than others, but you know, these thyroid nodules you like you have, they’re very, very common now. Very common. And that’s you know. In large measure, I think these hormone interrupters that are interfering with how the the thyroid follicles in the thyroid gland are operating. Bill Gasiamis (15:13) Is it possible to have thyroid nodules and not know about it? I, I Dr Hedaya (15:18) Yeah. Bill Gasiamis (15:19) say that because I had nodules that were the size of a baseball, apparently in my throat that were growing inwards, that didn’t make a lump outside of my throat, which Dr Hedaya (15:33) Yeah. Bill Gasiamis (15:34) I was not aware of. And the way they found it was they did a chest X-ray after brain surgery because I wasn’t recovering well. to check my chest to see if there’s an infection. And they noticed a massive lump in my throat and my esophagus and my windpipe were pushed six centimeters. Dr Hedaya (15:52) Wow. Bill Gasiamis (15:53) I’m not sure what that is in inches. And they said to me, well, can you swallow? Can you breathe? Can you do it? And I was like, yeah, I’m all fine. There’s nothing wrong with my throat. But that was the first sign that there was something wrong with my thyroid before that. there was no sign of it. I ask that because either I’m totally oblivious or it is possible to have thyroid nodules and not know it. Dr Hedaya (16:23) Well, most people don’t know it. Now yours is so massive, but I think it’s kind of what you said is how it grew. If it grew towards your vocal cords or your laryngeal nerve or something, you would have had some pretty bad hoarseness or something like that. But it grew I guess backwards so it didn’t interfere that much. And I guess your s your body adapted gradually over time. You know, yes, it’s very possible for sure. Very common. Bill Gasiamis (16:49) And how would somebody interact with a general practitioner, for example, now to go through the process of understanding, A, their thyroid health and whether or not they have any nodules. Navigating Thyroid Health with Healthcare Providers Dr Hedaya (17:02) I mean in other words, given what we’ve talked about, how should they approach their doctor basically? Bill Gasiamis (17:07) Yeah. Dr Hedaya (17:08) I guess I would say go to AI, get a list of the symptoms of low thyroid or high thyroid or all of them, check them off. So then when you go to the doctor you have a list, check your temperature, check your pulse, although the doctor will should check that. And then you could say, look, I have these symptoms, or maybe you don’t have any. But if you do, you have these symptoms, and clearly thyroid hormone levels can affect the brain. And I’d like a TSH, a free T4, a free T3, and a reverse T3. That’s it. And if they Bill Gasiamis (17:45) Okay, perfect. Dr Hedaya (17:46) say, no, no, we don’t need to do that, you know, a lot of times what they do, they’ll just do a TSH. Or they won’t do the reverse T3. They don’t, unfortunately, look at the thyroid gland in a dynamic way. They say, the TSH is fine. If your thyroid was low, your TSH would go high. We don’t need to do the rest. But that’s not true. That’s not true at all. Because especially if you had a stroke, your pituitary function may be compromised. Your TSH may be fine or low and your low thyroid. As matter of fact, in the last interview, the case that I talked about, who referred me to you, she actually had a low TSH, but she had a very low, I think it was a free T4. Or free T3 or both, whatever it was, but she had too little thyroid hormone, and her pituitary couldn’t respond because of the stroke. Bill Gasiamis (18:37) understood. So that’s a great list of Dr Hedaya (18:37) So so be you have to be dogmatic and you say to the doctor, look Even put into even put into AI and say, look, if the doctor comes back to me and argues against these tests, what should I say? You gotta be prepared because the doctor will steamroll you. You know, that they only allow this, they only allow that, I’ll only do the free T4. Well, that doesn’t tell you how much has been converted to T3, free T3, and it doesn’t tell you, even if the free T3 is normal, that doesn’t mean you’re not overproducing thyroid and and dis you know, and neutralizing it with the reverse T three. So, you know I mean I I mean I think it’s s so important that a thorough look is is really important. If you have the symptoms, you know. Bill Gasiamis (19:22) I agree with you. That list of to-dos, I’m gonna put that on the show notes. People can go and get that list if they don’t wanna go into AI themselves or they haven’t got the time or whatever. They can just download it from there. And then they’ll be able to take that and begin a conversation with their general practitioner. What’s interesting is that I’m in Australia, you’re in the United States. My general practitioner is pushed back when a… when a patient will turn up and say, I have these tests? They’ll say, well, no, you don’t have any condition that is obvious that you need these tests. So it’s not covered. So you don’t need to do it. So my next suggestion to them is no problem. Order the tests and I’ll pay for them. Now it’s not ideal, but if you’re not going to do them for me and I need to know, cause it’s my health, I’m going to pay for them. So just tell me how much it is and I’ll find a way and I’ll make it happen and I’ll pay for it. So that’s another option. Dr Hedaya (20:17) Yeah. But if you go in with your symptom list, right, and you say, Well, that’s not true, because these are the symptoms, you know, that I have, here they are, right here. You can take a look, you know. And then the last thing I’ll say, this gets even more tricky, is the reference range, I’m sure in Australia, but certainly in the United States, the reference range basically is of the TSH, the pituitary home. Is 0.5 to 4.5, meaning you anywhere in that range and your TSH is normal. That is a bad reference range. And I know it to be a fact because I I I guess I won’t waste your time with it, but I did a study on a hundred people and with a very sensitive thyroid test called a TRH stimulation test. and I was able I hired a statistician to calculate this. And say, well, I don’t want to keep doing this test on everybody. What TSH predicts an abnormal TRH stimulation test? And he came back and said to me, Well, once the TSH is over 1.4, it starts to increase your odds of having an abnormal TRH stimulation. So I said, okay, so 1.4 TSH is my cutoff, right? That’s in my mind. I said, okay, that’s that’s my cutoff, that’s when I get suspicious. Later, several years later, a paper came out, a large, large study, called the NHANES Study, Nurses Health, and I’m not sure what it stands for. Thousands of people followed over many, many years, over decades, and they found the mean TSH in the US population is 1.4. So, right where I what right where my study found. So that means statistically, it is not. impossible to have the upper limit of the reference range being at four point five because statistically the upper limit is never more than two standard deviations. So even if your standard deviation is 1.4, which it can’t be, you you’re not going to reach 4.5, right? Unless you have a it’s called a bimodal distribution curve. If you have that, then you’d say, well, it it could be. But we don’t have that with thyroid. So that reference range is wrong. The upper limit of the reference range should be 2.5. And about half the endocrinologists in the United States believe that. And half say, no, no, no, don’t change it. So that’s another sticky point because, you know, easily people get a result and they’ll go to the doc and say, no, the reference range is 4.5. You’re normal. Then you could say, well, look, I have these symptoms, and they could do a literature search. What’s the normal reference point? What in in the N A N HANES N-H-A-N-E-S study? It’ll show you 1.4. and you could take be prepared to go to the doctor and say, Well, here’s a study that suggests that the reference range may be incorrect. and I have symptoms by the way. We don’t treat the lab, we treat the person. So could we give a trial? Just a trial, there’s no harm done, you know, trial. Let’s see let’s start at a very low dose. Let’s see how I feel. Maybe I’ll get better. I’ll come back in a month. Bill Gasiamis (23:45) Yeah, I love that. It’s really good advice, especially coming from someone who is a doctor who think is thinking on the same way as me, for example, the patient. Because that’s like a match made in heaven. And that’s so rare to be able to get that. Often, my challenge to my general practitioner was well, the reference range isn’t that average of a sick population, because it’s usually a sick population that comes to see you to get bloods. It’s It’s not the most healthiest people that come to see you to get bloods. And that’s kind of how I try to like start the conversation of convincing a general practitioner to do a test that they’re reluctant to do. And when I say they’re reluctant, I’m not in there every day. I’m not in there every week. And I’m not putting stress on the system to an extent where I’ve been over using the system. I’m not at all. in there once, twice a year, maybe, you so if I’m in once, twice a year, well, then, I’m not mucking around. Like I’ve come there to investigate something that I’m suspecting is wrong with me. It’s my body. I’m feeling something. had a bit of a look online. This is what I suspect. Don’t try and convince me out of my thinking or my instinct more better. Why don’t we just, work together to get to the bottom of it. If it is something it is, if it’s not, it’s not, and that’s okay. Not a big deal. I’m better to know. then not no, I think, you know, it’s better to be safe than sorry in my mind. Dr Hedaya (25:16) Yeah. I would I would only think only correction I would make is the reference ranges generally are made on normal populations. Now now the thing is who’s normal anymore? Number one. Number two, that’s a statistical norm that doesn’t tell you anything about your genetics. your vulnerabilities, it’s not an individualized statistic. I mean it’s it not an individualized thing. What’s your normal range? And are you out of your normal range? Nobody can answer that, right? Unless you had previous data before you were ill. And you say, well look, I’ve been running at a 1.1 for five years or 10 years and now I’m at 3.2. That’s a big change. Well, you know you’re stressed. Well yeah maybe but here are my symptoms. Always come back to your symptoms. Bill Gasiamis (26:11) Got it, got it. Dr Hedaya (26:12) No. Bill Gasiamis (26:13) You use the word stress just now and my general practitioner says, I might go in and some bloods might be out of whack or some things might be not feeling great. And he’ll say, are you stressed? And I’m like, well, I’m not stressed. like, I’m not stressed in any way that I can say is worse than normal. For example, I’m Dr Hedaya (26:35) Mm-hmm. Bill Gasiamis (26:36) just, you know, I’m attending to my clients at work. picking up the kids from school, I’m, you know, making sure the bills are paid. Like I’m just doing the normal things that I always Dr Hedaya (26:48) Right. Bill Gasiamis (26:48) do, which tend to be stressful. And somehow when we talk about stress, cortisol seems to come into the conversation. Dr Hedaya (26:57) Mm-hmm. The Role of Stress and Cortisol Bill Gasiamis (26:58) And I don’t know how to respond to a general practitioner who says to me, am I stressed? Because I’m not experiencing something extreme or dramatic. in the months before I came to see him. So can we have a conversation a little bit about stress, cortisol, what is stress, what is cortisol, are they linked? Tell me about that, give me your thoughts. Dr Hedaya (27:21) Okay. Okay, so this is a multi-layer system. Okay, it starts with your perception and your of a situation and the story you tell about you the story you tell yourself about the the situation and your need for control of a situation and as opposed to saying I’m in the flow of the universe and All right, this is you know, this is the way it is, and I’ll adapt to it. Not so easy by the way, but it’s a much healthier way because most things will not stress you. Now, pain, let’s say you stepped on a nail, you’re gonna have stress, okay? Totally stressful, etc. But there’s a a difference between pain and suffering. Most of our problem is suffering. Suffering is a result of thinking patterns. perspectives of yourself and the world and the future and blah blah blah. I could talk about that for a long time. And that is probably one of the most important places to intervene and to train yourself, etc. Now, once this thing is registered as stress, it goes through back to the hypothalamus and the pituitary where all those hormones are controlled, the hypothalamus and pituitary in the brain, now you’ve God forbid, you’ve had a stroke. Those things may be affected, therefore, those systems may not be working well. In that case, you may not be able to handle stresses that you used to handle. You may not you may not have those shock absorbers. So, how do you measure this? I think the way you measure it again are symptoms, and typically it would be low cortisol and low DHA, d DHEA, and low pregnenolone. And the symptoms would be a lot of fatigue, right? Maybe poor wound healing, muscle aches, body pains, getting sick more easily, cognitive slowing, depression, anxiety, extreme exhaustion, salt cravings, in unstable temperatures, you know, I would say yeah You know, th loss of appetite in severe cases, you know, dizziness on standing. Okay. So those are the low adrenal output things. Now how d how do you measure and again, you think you have a problem, go to an AI thing, make that list, check it off, whatever applies, and you know, work yourself up symptomatically and then ask well, okay, what what are the best tests here? What are the best test. Now the way I test it is I get morning I got a morning like eight to nine a.m fasting ACTH and cortisol. It’s gotta be in the morning around between eight and nine a.m. fasting. I also at the same time get a D, like David, H E A and a D H E A sulfate, and then I also get a pregnenolone. And if I think there’s any kind of sex hormone problem that I want to check, then I will check a free testosterone, FSH, LH, and The testosterone measures the free testosterone is very unreliable. So if it comes out low, you want to do it two more times to double check that. But the other measures are pretty reliable. And then you’ll you’ll know the other thing you can do is you could do something called a Dutch test, which is a urine test that’ll look at your cortisol through the day, or an adrenal saliva test. It’s ASI, alleval adrenal saliva index, the Dutch test. or the ASI, both good tests. and those will tell you what’s going on through the day. Like if you’re not sleeping, it could be because your cortisol high at night, you know. Wake up horrible or in pain. Could be because your cortisol is really low in the morning. Really low. You can’t even get out of bed, you know, can’t get going, right? So these are all all things that you can do to measure and then you can replace these hormones and That’s one thing to do. The other thing to do is to work on how you manage stress. There are millions of ways of doing that, right? From meditation to heart math to Bill Gasiamis (32:05) Mm-hmm. Dr Hedaya (32:06) yoga to you know, there’s just a lot a lot a lot of ways to Bill Gasiamis (32:10) Yeah, let’s go back for a moment and talk about testosterone because when I hear testosterone, I’m hearing you say to a male that I need to have testosterone in my body and at certain levels, et cetera. And sometimes it can fall out of whack and you need to get it tested. I had mine tested recently. It’s all good. But women also need testosterone. Tell me about that. Dr Hedaya (32:35) Yeah, so I was I was thinking of both male and female when I said it, Bill Gasiamis (32:38) Yeah. Dr Hedaya (32:39) because it’s it’s you know, women who are postmenopausal can have it’s much more common to have a low free testosterone loss of libido, you know. testosterone the studies which I’ve reviewed a few times, you know, there’s a debate does it affect the mind, the brain, you know. It seems to have an effect on well being, on vitality muscles, sex drive obviously, libido erectile function, brain cognitive function, some mood effects, etc. So I I think it’s important now i it it has to be managed in women as well as men. You know, in in women testosterone is a step on the way to estrogen as it is in men, right? And in the metabolism, right? So it it should certainly be assessed in everybody. Bill Gasiamis (33:39) Yeah. And estrogen, mentioned estrogen. Now, one of them in my mind, it seems to be more associated again to women, estrogen, especially. And, and then men also have estrogen, need estrogen. Dr Hedaya (33:55) Men also have estrogen. I haven’t studied it so I couldn’t tell you, but I imagine it’s doing something. it probably turns men into better leaders after they’re fifty, is my guess. Let Bill Gasiamis (34:08) more emotionally intelligent. Dr Hedaya (34:10) more emotionally intelligent, less testosterone, you know. You know, I I I Bill Gasiamis (34:15) You know what? That’s a good theory. We’ll run with that for now. I might relate to that, know, who knows. Dr Hedaya (34:22) Yeah. I I think Bill Gasiamis (34:24) Awesome, awesome, so… Dr Hedaya (34:24) Yeah, so w for for women on estrogen, it depends, you know, who are you assessing? Are you that’s a whole complex subject, you know. Is it a young woman who’s menstruating? Does she have premature ovarian failure, endometriosis, ovarian cysts, insulin resistance, they all kind of travel together, methylation problems, they travel together. is it someone who’s perimenopausal where she’s starting to lose progesterone and getting a lot of PMS? That’s pretty easy. You can replace the progesterone. Is it postmenopausal a woman who’s just kinda lost the estrogen, lost the progesterone? You know, if there’s a family history of cognitive decline or dementia or something like that, there’s great evidence that transdermal estrogen and some oral progesterone bio bioidentic, not synthetic, is great and reduces the risk for lots of disorders later in life for women. You know. So there’s a whole you know, there’s a whole way of working all that up, depending on who who you’re looking at. But very important. Now so the let me Bill Gasiamis (35:31) Yeah, I love it. Yeah. Dr Hedaya (35:34) say this. The important thing here, and this is maybe the most important thing. Someone’s had a stroke, they’re obviously tremendously stressed. You have to look at all the hormones. You can’t the brain is a hormonal organ. It’s an immune organ. It’s a neurological organ. I used to teach psycho, neuro, immuno, and the chronology at Georgetown for a number of years. Okay? And the brain and hormones, you can’t separate it. So if the brain is under stress, the hormonal axes are under stress, and there’s not one hormonal axis when it’s abnormal that cannot cause neurological or psychiatric problems. Okay? So you must, as part of the work of anyone who’s had stroke. You must look at the endocrine, the hormonal axis. You know, you must look at it. Why? Because if you’re trying to recover from a stroke and you don’t have adequate hormones, it’s gonna be much, much harder. Much, much harder. Right? But Bill Gasiamis (36:37) Peace. Dr Hedaya (36:38) if you have if you have the the hormones at good levels, okay, now the the brain has that. If it has its nutrients, it has that, you know, okay, now it can do something, you know. What happens, think about it this way. What happens in adolescence? The brain is being rewired, the body’s growing, brain is rew being rewired. Where are the hormones? The hormones are skyrocketing. They’re necessary for the rewiring. You had a stroke, you’re trying to rewire brain, you gotta have adequate hormones. Bill Gasiamis (37:10) I love it. This is the thing that people miss. You know, we talk about the gap in stroke recovery. Acute phase gets handled Dr Hedaya (37:19) That’s Bill Gasiamis (37:19) 99 % of the time really well. People get patched up and they get sent home in some kind of alive state, whether they are fully functional Dr Hedaya (37:27) Yeah. Bill Gasiamis (37:28) or working towards it or whether they are less functional and working towards being more functional, like some kind of stage Dr Hedaya (37:35) Mm-hmm. Bill Gasiamis (37:36) of you’re alive and you’re good enough to go home. And then there’s no information after that. So how do we assess address? How, what do we know? What do we not know that we need to know? And this is kind of what this conversation is, right? It’s like, okay, here’s Dr Hedaya (37:53) Yeah. Bill Gasiamis (37:53) a whole bunch of things we’ve just discussed. There might have been things that you heard for the first time. Don’t let that, get in the way of your curiosity and investigate the thing that pricked your ears up, whether it was a symptom that Dr. Hedaya mentioned and just do a little bit more work in understanding what that is, take that to your general practitioner and begin the conversation of taking responsibility for your recovery. And in my mind, like there’s gotta be like a foundational thing that people can do to intervene that doesn’t cost most of the time anything extra. And that helps encourage and nourish the brain in overcoming these challenges, but then has the a cascade effect of having the same positive outcome on all the other organs and hormones. And that to me is nutrition. So like, if you’re, if you would suggest to somebody how they might start thinking about their nutrition as opposed to what they might have been doing before stroke, how do you begin that conversation? And what are the two or three fundamental things that they need to consider? about nutrition. Nutrition’s Impact on Brain Recovery Dr Hedaya (39:11) Okay, so If it doesn’t grow that way, don’t eat it. I never saw a bread tree. I didn’t see an ice cream tree or a Twinkie tree. Okay. So if it doesn’t grow that way, don’t eat it. Balance your plate. Balance your plate. And actually our coach, Caroline Hade, is putting out an ebook. I don’t know, should be out at a week or two or three weeks. It’s like, I don’t know, four or five dollars or something. and that will tell you exactly how to balance your plate. and then I would say very important to have three meals and maybe, depending on your how insulin resistant you are, maybe additionally two snacks. and per day, but keep your calories you don’t want to be overweight, okay, because if you’re overweight, you know, that’s a That’s its own risk factor for brain problems, right? but you can’t lose weight in a day, you’re stressed, you’re hungry, you’re tired, you eat the carbs, you know, everybody struggles with that. But that that is one of the biggest enemies of eating eating eating these processed carbs that we all love is one of the biggest enemies of your health. One of the biggest enemies of your health for sure. Bill Gasiamis (40:35) Okay, there are some great resources that people can again look into how to eat to heal the brain. And we didn’t have to have a deep conversation about that. But I love Dr Hedaya (40:45) Mm-hmm. Bill Gasiamis (40:45) what you said about balancing the plate. And if it didn’t grow that way, don’t eat it. It’s such a simple thing. If it comes in a packet on a shelf in a supermarket with all fancy pictures Dr Hedaya (40:59) Yeah. Bill Gasiamis (41:00) and stickers and a list of ingredients, like it’s probably not nutritional. of food. It’s probably something that’s going to make inflammation worse. It’s probably something that’s going to give you the type of energy that is not helpful. It’s probably going to have a whole bunch of other things. And that’s kind of my approach to healing and recovering my brain. It’s one of the first things I did was just look at my nutrition, immediately stop smoking and drinking. mean, I know it should go without saying, but sometimes you have to have a stroke for it to actually sink in and make sense. and don’t have any alcohol at all. I’m talking about forever if you can, but I didn’t have alcohol Dr Hedaya (41:46) Yeah. Bill Gasiamis (41:47) for at least the first four or five years. And now in the next five years or so, maybe I had one glass per year, just because I was, in an event where it was, everyone was drinking and it was almost necessary to have sip or half a sip or act as if I was drinking. So with that, I think we’ll wrap up this conversation today. There’s been a lot for people to digest, go back and listen to it a second time. And a third time that we have some resources in the show notes. And Dr. Hedaya, thank you for joining me again. And I look forward to our conversation that’s coming up in a few weeks time where we’re going to talk about toxin load and neuroplasticity. Dr Hedaya (42:29) Beautiful. Thanks so much for the opportunity, Bill. I hope I hope people get something out of this and they pursue what they need to pursue. Bill Gasiamis (42:36) Well, that’s a wrap on this conversation with Dr. Robert Hedeya. If there’s one thing to take from today’s interview, it is this. The brain is a hormonal organ and recovery isn’t just about the brain healing in isolation. Thyroid, cortisol, testosterone, estrogen, all of it is connected, and all of it is worth checking if your recovery has plateaued in ways that don’t quite make sense. Dr. Hadea’s free PNIE questionnaire is linked in the show notes. Download it, work through it, and take it with you to your next GP visit. If you want to go deeper on the thyroid piece specifically, go back and listen to the earlier episode with Dr. Elena Zinkov on stroke fatigue and thyroid. And if you missed it, the first conversation with Dr. Hedeya on photobiomodulation is a great companion to this one. if this episode has helped you, share it with someone who needs to hear it. That’s genuinely the best way to help this show reach more survivors. My book, The Unexpected Way That a Stroke Became the Best Thing That Happened, is available at recoveryafterstroke.com/book. And if you’d like to support the show financially, you can do so at Patreon by going to patreon.com/recoveryafterstroke. Until next time, take care of yourself and don’t assume it’s just a stroke. The post Hormones, Fatigue, and the Brain: Dr. Robert Hedaya Returns appeared first on Recovery After Stroke.

GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/wam USE Code WAM to save 25% plus free shipping! USE Code WAM50 for 50% off on select items like the #10 cans & MRE packs! Pledge here! Just a dollar a month can help keep us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 EXCLUSIVE replays of hour plus long live shows are available here at $5 a month or more! GET 10% OFF ON SHILAJIT FROM DR. KAUFMAN WHEN YOU USE CODE WAM10 HERE: https://medauthentica.com/discount/WAM10?redirect=/products/authentica-shilajit%3Fsca_ref=10867124.wrNV3jkYSaMg9 Josh Sigurdson reports on the kickoff of mRNA cancer vaccine trials by Moderna. Ironically, Moderna which admitted themselves in their papers shown in front of Congress that their mRNA covid vaccines cause cancer are now running a trial to "cure" cancer with mRNA. mRNA notoriously leads to cancer cell growth in studies. 65% of new cancer cases received one or more Covid vaccines according to Croatian pathologists. Cancer cases in England have hit record highs. Billionaire cancer researcher and owner of ImmunityBio and The Los Angeles Times Dr. Patrick Soon-Shiong claimed covid vaccines were likely causing the massive increase in cancer cases. The Former Japanese Minister of Internal Affairs Kazuhiro Haraguchi proved he got cancer from the mRNA covid vaccine with an independent review and study. A South Korean study of over 8 million people proved covid vaccines caused an increase in cancer risk across the board, in some cases massively. On top of Moderna acknowledging their vaccines cause cancer, Pfizer was also caught withholding evidence of the presence of cancer-linked DNA in their covid vaccines (SV40) which came out in court. Pfizer's CEO Albert Bourla also claimed in May of 2024 that cancer "is our new covid." He spoke about how much money he could make off of cancer following the covid vaccines as they are themselves involved in cancer vaccine development using mRNA. This is truly evil. Meanwhile, our foods are being sprayed with cancer causing chemicals. Our water is toxified by hydrofluosilicic acid (industrial fluoride). Then these pharmaceutical corporations come in as a "solution" utilizing the very things that cause cancer in the first place to "cure" it. Insanity. In this video, we delve into the dangers of mRNA cancer vaccines based on what acclaimed doctors are saying. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2026

[20260717] Crónicas de San Borondón Crónicas de San Borondón continúa estirando su decimoséptima temporada en la Radio Canaria con una nueva entrega este viernes 17, un programa en el que pondrán el foco en una de las figuras más misteriosas y cambiantes de la tradición judeocristiana, Lilith. De acuerdo con la tradición, habría sido la primera mujer, creada antes que Eva y hecha del mismo barro que Adán. Desde ahí su figura ha evolucionado con el tiempo hasta convertirse en un ícono de las reivindicaciones feministas. Ricardo Martín ahondará en todos sus significados y en los posibles motivos de su éxito entre del mundo del mito. Visitará el programa Dolores Bolaños, escritora y experta en esoterismo que se define como una «bruja moderna». Bolaños es autora del libro Pa Bruja Yo , donde comparte los conocimientos que sobre medicina tradicional canaria atesora por vía familiar, con prácticas procedentes de otros marcos culturales con los que ha entrado en contacto. Los contenidos de esta semana se completan con la participación del investigador canario José Gorrín, experto en temáticas conspiranoicas y un perfil muy activo en foros y rrss especializadas en el fenómeno OVNI, quién compartirá la última hora sobre ese amplio ecosistema de creencias y narrativas alternativas a las versiones oficiales sobre la realidad, además de narrar algunas de sus experiencias personales como testigo de fenómenos sin una explicación aparentemente convencional. Además, en sintonía con la gran expectación y el debate internacional generado por la última película de Steven Spielberg, El Día de la Revelación, el experto en cine Manuel Díaz Noda y José Gregorio González, charlarán sobre las reacciones desencadenadas por la cinta y las motivaciones reales tras la misma. «Será, una semana más, un programa de contrastes, donde la potencia del mito a través del tiempo de la primera mujer se verá las caras con otro escenario igual de evocador, que ha cristalizado en el cine, el del contacto con los seres del espacio. Todo ello, además, en un programa con dos perfiles de invitados que ven los temas misteriosos desde la óptica de quienes han sido protagonistas de hechos sin aparente explicación», apunta José Gregorio González.

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. La posizione politica sui casi di di Mario Roggero e Fakir , il nuovo premier britannico Burnham, la guerra in Medio Oriente, la stretta dei NAS sulle piscine. Spazio Donna Moderna. Le relazioni parasociali. Ne abbiamo parlato con Giulia Scolari, di Donna Moderna. La preoccupante crescita del prezzo dei carburanti. Ne abbiamo parlato con Mauro Antonelli, dell'Unione Nazionale Consumatori. Situazione Baby Gang. Ieri una imponente operazione della Polizia in 44 province. Il punto con Maura Manca, psicologa e psicoterapeuta, presidente dell'Osservatorio Nazionale Adolescenza e con Stefania Crespi, Avvocato penalista cassazionista. Questo è l'anno del Glamping. Ne abbiamo parlato con Alberto Granzotto, presidente di FAITA Federcamping, la Federazione Italiana del Turismo all'Aria Aperta, e vicepresidente nazionale Confturismo. L'attualità, commentata dall'editorialista del giornale Repubblica, Maurizio Molinari. All'interno di Non Stop News, con Giusi Legrenzi, Lucrezia Bernardo, Enrico Galletti e Massimo Lo Nigro.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

"I always remember feeling like I was part of the clean plate club," says Dr. Christle Guevarra, recalling a childhood spent quietly convinced that her weight was a matter of willpower. That belief followed her through a competitive powerlifting career and medical practice until she finally tried a GLP-1 medication herself and, as she describes it, the constant mental noise around food quieted down. Now a board-certified family and sports medicine physician, traveling team doctor for U.S. Figure Skating, and author of The Beginner's Guide to GLP-1s, Dr. Guevarra brings a rare combination of clinical authority and lived experience to the conversation around obesity medicine.  In this episode of Raise the Line from Elsevier, host Lindsey Smith talks with her about what's actually changed in how physicians understand the issue and what it means for patients. "The biggest thing is reframing how we approach weight loss. It's not just a willpower problem, it is a neurobiological problem." Tune in to learn about: Why she said no to a GLP-1 prescription for two years and what finally changed her mind; The real story behind concerns about muscle loss on these medications; What happens when the “food noise" goes silent and a new set of challenges takes its place.   Mentioned in this episode:  Dr. Christle's website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Deputāti komisijā atbalsta ieceri veidot īpašu fondu Latvijas austrumu teritorijas attīstībai; jālemj būs Saeimai. Joprojām asas diskusijas par vēja parka ieceri Augšdaugavas novadā. Lietuva un Polija brīdina par iespējamiem Krievijas provokāciju scenārijiem. Modernas un drošas telpas, plašākas ārstniecības, aprūpes un diagnostikas iespējas – tas tiek solīts jaunā Plaušu veselības un infekcijas slimību korpusa pacientiem Rīgas Austrumu klīniskajā universitātes slimnīcā. Ir sagatavoti priekšlikumi informācijas un komunikāciju tehnoloģiju iepirkumiem. Priekšlikumus izstrādājusi Viedās administrācijas un reģionālās attīstības ministrija kopā ar IUB un Finanšu ministriju, atsaucoties uz premjera rezolūciju.

Abrimos La Ventana de los libros para entrevistar a la escritora Mar Horno. Vuelven el concurso de Relatos con banda sonora con Miguel Ángel Marcos, profesor de los cursos del Área de Creación Musical de Escuela de Escritores, músico, productor y compositor,  que será el encargado de convertir el microrrelato ganador del concurso en una canción que se estrenará el próximo lunes 31 de agosto; y Beatriz Díaz Rodríguez, ganadora del concurso de año pasado.  Ana Valtierra vuelve con su sección La casa azul y Pilar de Francisco se encarga de cerrar este tramo. 

Antes de la Revolución Industrial, la medicina se había estancado en un estado de desarrollo similar al de la Edad Media. Proliferaban las enfermedades, y el promedio de vida apenas alcanzaba los 36 años. En este episodio relatamos la asombrosa historia de los pioneros de la razón y de la ciencia que desafiaron al viejo orden. James Lind dirigió el primer ensayo clínico, el cual confirmó que era posible prevenir el escorbuto y salvar las vidas de miles de marineros utilizando naranjas y limones. Edward Jenner, un médico preocupado por las hermosas lecheras, utilizó su capacidad de observación y el pensamiento lateral para encontrar una vacuna contra la viruela. El doctor René Laennec era terriblemente tímido. No soportaba la idea de tener que acercar la oreja a los pechos de sus pacientes femeninas. Por eso inventó el estetoscopio, un instrumento clave a la hora de diagnosticar que hoy se ha convertido en un icono de la profesión médica

Millions of Americans were saddened and outraged by the Sandy Hook Elementary shooting in 2012 that took the lives of twenty children and six adults, and were left feeling helpless about the epidemic of gun violence in the U.S. that, sadly, continues to this day. But for our guest today, Shannon Watts, her feelings of devastation about the shooting turned to rage and fueled her unlikely rise to leading Moms Demand Action, which she grew into one of the largest grassroots organizations in the country, mobilizing millions of volunteers to push for stronger gun safety laws. “I wanted to stand shoulder to shoulder with a badass army of women because that's who gets things done in this country,” she says.    In this inspiring conversation with Raise the Line host Michael Carrese, Watts pulls back the curtain on how the group achieved its successes and the philosophy of "losing forward" that kept volunteers showing up year after year. In her recent book Fired Up, Watts describes how she is bringing insights from that experience to a new mission: helping women identify their values, abilities, and desires and acting on them without waiting until everything is perfect. Tune-in to learn about:  The "false fires" women mistake for passion; Why losing estrogen and testosterone in midlife might actually make women braver, not less so; The one exercise she does with every woman she coaches.  Mentioned in this episode: Fired Up book Moms Demand Action If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Noubar Afeyan helped bring one of medicine's biggest breakthroughs to the world through Moderna's Covid-19 vaccine. In this episode, he explains why what looked like an overnight success was actually decades in the making.Presenter: Will Bain Producers: Barbara George and David Cann Researcher: Aleeza Siddiq

La cancionera mexicana Avelina Landín con el trío 'Tamaulipeco', desde los estudios de la Radio Cadena Suaritos, nos recuerda el esplendor de La Habana como plaza artística donde numerosas figuras extranjeras conquistaron el éxito. Y de tierras aztecas también llegaron los charros con su vestuario típico, los mariachis y, por supuesto, aquel repertorio popularizado en cientos de películas. Tito Guízar, finalizando los años 30, fue el primero en poner de moda en las pantallas cinematográficas la figura del "charro cantor". Las antenas de la CMQ nos devuelven, en vivo y en directo, el arte de aquellos astros del cine de oro azteca. A continuación Jorge Negrete con el trío "Calaveras" y Pedro Infante con el mariachi "Vargas". Apoyo de la Orquesta CMQ bajo la conducción del maestro Enrique González Mánticci. Unos minutos más recordando a estos valiosos artistas que llegaron a La Habana en busca de reconocimiento y éxito. El Trío "Janitzio" se presentó en la Habana de marzo de 1945. Emisiones históricas de la Mil Diez. Graciela Pérez durante décadas identificó, junto a su hermano Machito, la sonoridad de los "Afrocubans". Sin dudas una de las bandas más progresivas del Nueva York de comienzos de los años 40. Bajo la guía musical de Mario Bauzá, sus formidables cualidades interpretativas, acompañadas de un notable desenfado escénico, le concedieron el éxito. Falleció en Nueva York, la ciudad de sus grandes éxitos, el 7 de abril de 2010, a los 95 años. Nos acercamos brevemente al álbum 'Con el permiso de Bola', producido por Warner Music de México en 2006 y protagonizado por Pancho Céspedes y Gonzalo Rubalcaba. Así celebramos el premio a la Excelencia Musical con que la Academia de los Latin Grammy ha distinguido la trayectoria artística de Pancho Céspedes. Merecido reconocimiento al maestro quien, a lo largo de su carrera, ha dejado huella en los escenarios del mundo en su doble condición de compositor e intérprete. Muchas felicidades le deseamos al maestro Pancho Céspedes. La era de los cuartetos vocales comenzó a cobrar fuerza en Cuba, a mediados de los años 40, de la mano de relevantes pianistas como Isolina Carrillo, Orlando de la Rosa, Facundo Rivero, y Bobby Collazo, entre otros. Para la década siguiente el auge de clubes y cabarets favoreció la aparición de otras formaciones dirigidas por otros pianistas como Mario Fernández Porta y Carlos Faxas. Sin embargo la más sobresaliente resultó ser el cuarteto organizado por Aida Diestro en 1952. Con una marcada presencia en esos espacios, así como en los directos de radio y televisión, el cuarteto D'Aida iluminó los escenarios con su espléndido empaste vocal y armónico en función de un selecto y variado repertorio. En las pistas de emblemáticos sitios de la noche habanera como "Tropicana" y "Sans Souci" desarrolló magníficas temporadas. En el 96 aniversario de su natalicio recordamos a Tata Güines. Auténtico orfebre del sabor, siempre reconoció el arte de los percusionistas que le antecedieron, entre ellos Carlos Patato Valdés a quien invariablemente señaló como el primero en haber utilizado dos tumbadoras con afinación. Tata, finalizando los años 50, ya era elemento a tener en cuenta en el ambiente de las descargas, los shows de radio y televisión, así como las numerosas producciones que, casi a diario, generaba una industria discografica independiente y en franco desarrollo. En este último apartado tuvieron absoluta importancia en su carrera las llamadas "descargas en miniatura" de Cachao López y el debut del Quinteto de Música Moderna con el pianista Frank Emilio Flynn a la cabeza. Tata Güines en la memoria.

This week primary care physicians Kate Rowland, Mark Ebell, Gary Ferenchick and Henry Barry discuss four new studies: screentime for children, discontinuing levothyroxine, a new mRNA flu vaccine from Moderna, and nicotinamide adenine dinucleotide (NAD) Supplementation for healthy aging.Links to articles:AAP screen time policyDiscontinuing levothyroxine studymRNA flu vaccine from ModernaNAD supplementsQuiz: Bixomania study

In the United States, nearly 70% of people say they want to die at home, yet the majority still die in medical settings, often after receiving care that may not match their goals and values. Closing that gap between preference and reality is at the heart of the work being done by End Well, a nonprofit dedicated to transforming how we think about, plan for, and experience the end of life. "The gap isn't about people wanting the wrong things. It's that our culture and our incentives aren't aligned with helping those wishes actually happen at the end of life,” says Dr. Shoshana Ungerleider, End Well's founder and president.  As Dr. Ungerleider explains to Raise the Line host Michael Carrese, End Well sponsors an annual symposium and year-round activities to bring together clinicians, patients, caregivers, and innovators to improve that alignment. Key steps include earlier integration of palliative care, allowing providers time for listening and goal setting with patients, and normalizing conversations about what matters most to people. This compelling conversation on reframing end of life care also covers how to bring wonder, joy, and hope into end-of-life conversations, and End Well's work to change how death is portrayed in the media. Mentioned in this episode:End Well If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry. Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel treatment aimed at preventing graft-versus-host disease (GVHD) in blood cancer patients undergoing allogeneic transplants. This approval emphasizes the potential of regulatory T cells in mitigating the severe complications that often accompany such transplants. The success of Tregzi not only marks a pivotal moment for cell therapy but also heralds a new era in transplant medicine where cellular therapies can significantly improve patient outcomes by reducing GVHD incidence. In other strategic moves, Ipsen's acquisition of Memo Therapeutics for up to $796 million highlights the industry's focus on addressing unmet needs in transplant medicine. Memo's work on monoclonal antibodies targeting the BK virus—a significant threat to kidney transplant patients—reflects a growing trend towards personalized medicine and targeted biologics. This acquisition is poised to bring much-needed therapeutic interventions to market, underscoring the sector's commitment to innovative solutions. Meanwhile, Anthropic is making waves with the introduction of Claude Science AI Workbench, accompanied by an internal drug discovery program aimed at neglected diseases. This initiative underscores the transformative role of artificial intelligence in drug discovery, particularly in areas previously overlooked due to limited commercial incentives. By accelerating the identification and development of novel therapeutics, AI-driven platforms promise breakthroughs in treating rare and neglected diseases. In clinical trial news, Abivax has reported promising Phase 3 safety data for obefazimod, a miR-124 enhancer targeting ulcerative colitis. By alleviating previous cancer-related concerns, obefazimod stands out as a potential small molecule oral therapy for autoimmune conditions. This advancement demonstrates ongoing innovation in small molecule therapeutics designed to modulate immune responses, expanding treatment options for ulcerative colitis patients. On the financial front, several companies are bolstering their pipelines through significant funding efforts. Alvotech has secured a $75 million term loan to enhance its biosimilar pipeline, reflecting the increasing importance of cost-effective biologic alternatives. AB Science has raised approximately $2.62 million focusing on oncology and rare diseases like acute myeloid leukemia (AML) and amyotrophic lateral sclerosis (ALS). Additionally, Flare Therapeutics' $85 million Series C round emphasizes precision medicine approaches targeting transcription factors, illustrating the industry's dedication to precision medicine. Regulatory landscapes are also shifting with Sarepta Therapeutics' FDA acceptance for full approval bids on Amondys 45 and Vyondys 53 despite confirmatory trial challenges. These therapies leverage exon skipping technology for Duchenne muscular dystrophy treatment, highlighting the intricate balance between accelerated approvals and robust clinical evidence requirements. In mergers and acquisitions news, Kimball Electronics' acquisition of Helvoet Polymer Technologies expands their drug delivery systems capabilities across Europe and India. This strategic alignment reflects broader industry trends towards integrated service offerings and global expansion efforts. Regulatory challenges continue with leadership changes at the FDA as Vijay Kumar steps down amid ongoing turbulence within gene and cell therapy sectors. Additionally, Angitia Biopharmaceuticals' termination of its Phase 3 trial for its BMP-6 candidate illustrates inherent risks and strategic pivots often necessary in drug development. Turning our focus globally, China's approval of its first CAR-T therapy for solid tumors signals a pivotal moment in oncology. This milestone could spur similar advancements worldwide, particularly drawing interest on when such treatments might receive approval in other regions like the United States. Moderna's expansion into in vivo CAR-T therapies for autoimmune diseases further marks a strategic divergence from traditional approaches, aiming to create off-the-shelf solutions that redefine treatment paradigms. Gene therapy continues to gain traction as Uniqure navigates regulatory reversals from the FDA regarding its Huntington's disease gene therapy filing for accelerated approval. This development hints at a broader shift within regulatory bodies towards fostering innovation in rare disease treatments under new leadership directives. Industry-wide trends also reveal a notable shift towards automation in cell therapy production led by companies like Cellares and Ori. This reflects growing demands for scalable manufacturing processes that enhance production capabilities while reducing costs. Overall, these developments illustrate a dynamic landscape where scientific innovations, strategic partnerships, regulatory adjustments, and technological integrations drive progress across various medical fields. As these sectors evolve, they hold vast potential for transforming patient care through groundbreaking therapeutic options and improved healthcare delivery systems worldwide.Support the show

¿Qué hace que una obra sea verdaderamente barroca? Más allá del exceso ornamental o la exuberancia visual, el Barroco fue una forma de entender el mundo: un lenguaje construido sobre el movimiento, la contradicción, el asombro y la conciencia de la fugacidad de la existencia. En este episodio exploramos los fundamentos de la estética barroca, desde su contexto histórico hasta sus principales conceptos: el claroscuro, la teatralidad, el dinamismo, la tensión entre apariencia y realidad, el *memento mori*, la vanitas y la búsqueda constante de lo sublime. Analizamos cómo estas ideas se manifestaron en la pintura, la escultura, la arquitectura, la literatura y la música, y por qué el Barroco sigue siendo una sensibilidad sorprendentemente contemporánea. A través de las obras de artistas como Caravaggio, Velázquez, Bernini, Rubens o Ribera, y del pensamiento de autores que han reflexionado sobre este periodo, descubrimos que el Barroco no fue simplemente un estilo artístico, sino una respuesta estética a un mundo marcado por la incertidumbre, la crisis y el deseo de trascendencia. Un recorrido por una de las épocas más intensas y complejas de la historia del arte para entender por qué la estética barroca continúa moldeando nuestra forma de mirar el mundo.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Biotech-Gewinner, die lukrative Nagarro-Offerte und das Halbjahres-Orakel. Außerdem geht es um GameStop, eBay, Moderna, Biogen, Apellis Pharmaceuticals, SpaceX, JPMorgan, Nasdaq, Nagarro, Persistent Systems, FactSet, General Mills, Constellation Brands, Tesla, CrowdStrike, AeroVironment, Apple, Microsoft, Amazon, Nvidia, Alphabet, Meta, Micron, BYD, Geely, Volkswagen. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Diese Folge enthält Werbung für Smartbroker+. Depot eröffnen, 30 € ETF als Bonus sichern und aus tausenden ETFs wählen. Smartbroker+ macht Investieren einfach. Alle Informationen gibt es unter: https://get.smartbrokerplus.de/triple-aaa-podcast2/ Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry. Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treating advanced melanoma. The FDA's acceptance after two prior rejections is significant, suggesting a shifting regulatory landscape that could favor innovative cancer therapies like oncolytic viruses. These therapies represent a novel approach to engage the immune system in targeting tumors, and if RP1 gains approval, it may open doors for similar treatments, potentially offering new hope for melanoma patients. On the regulatory side, Amgen has encountered challenges with Tavneos after losing European Union endorsement due to data integrity issues. This serves as a stark reminder of the critical importance of maintaining stringent data management throughout drug development. With an FDA hearing on the horizon, the implications are far-reaching, emphasizing increased scrutiny from regulatory bodies worldwide. This scenario could lead to more rigorous guidelines governing data practices in the future. The European Commission's approval of Henlius' Hetronifly as a first-line treatment for squamous non-small cell lung cancer marks a milestone in cancer immunotherapy. This approval highlights the ongoing efforts to improve patient outcomes through innovative PD-1 inhibitor-based combination therapies, showcasing progress in the fight against one of the most challenging forms of cancer. Epicrispr Biotechnologies brings promising news from its phase 1/2 trial of EPI-321, a gene therapy for facioscapulohumeral muscular dystrophy. The trial's success in enhancing muscle function through epigenetic silencing underscores significant advancements in gene therapy applications for neurological disorders. Similarly, Abbisko Therapeutics' phase 2 trial reports a 90% objective response rate using FGFR2/3 and PD-L1 inhibitors for gastric cancer, demonstrating the potential of targeted small molecule therapies in oncology. In financial developments, Definium Therapeutics and Ligachem Biosciences have made substantial funding strides to bolster their drug development pipelines. Definium's $805 million raise aims to advance psychiatric and neurological treatments, while Ligachem's funding will enhance its antibody-drug conjugate platforms. These investments reflect strong investor confidence in next-generation therapeutic platforms and underscore innovative financing strategies crucial for sustaining research and development efforts. Bayer's recent legal victory at the Supreme Court overturning a $1.25 million verdict related to its Roundup product is another focal point. This ruling not only positively impacts Bayer's financial standing but also highlights the complexities surrounding product liability cases within pharmaceuticals and agrochemicals. Strategically, Moderna has unveiled an ambitious R&D roadmap aiming for break-even by 2028 with over seven new products on the horizon. By focusing on mRNA vaccines for oncology and rare diseases, Moderna continues to leverage its technology beyond COVID-19 applications, potentially transforming treatment paradigms across various therapeutic areas. Shifting focus to industry trends, Sanofi finds itself under investigation by the European Commission for antitrust violations linked to its flu vaccine marketing practices. This situation underscores growing scrutiny over competitive practices within the pharmaceutical sector and could influence regulatory compliance strategies across global markets. In technological advancements, Eli Lilly is employing artificial intelligence to raise awareness about Alzheimer's disease through creative engagements like a European radio show road trip. These initiatives reflect an industry-wide shift towards technology-driven marketing strategies aimed at personalizing patient interactions. Lastly, Merck KGaA's $11 billion acquisition of Bio-Techne exemplifies a strategic move to enhance capabilities in immune cell therapy production. This deal underscores the growing importance of manufacturing innovations in bringing advanced therapies to market and highlights strategic collaborations increasingly seen across the sector. The landscape is further defined by significant scientific breakthroughs such as Revolution Medicines' development of a second RAS blocker, showing improved chemotherapy responses in pancreatic cancer patients. These advancements underscore the need for continued investment in targeted therapeutics research as they promise better patient outcomes and highlight ongoing innovation within oncology. As these developments unfold, they reflect an industry poised for transformation amid evolving scientific, regulatory, and market dynamics aimed at improving patient care globally. With these insights into current trends and future directions, it's clear that the pharmaceutical and biotech sectors are navigating a period rich with potential for groundbreaking advancements that will shape healthcare outcomes worldwide.Support the show

MAHA feels like a distant memory as we are not seeing any progress to speak of. The FDA voted 9-0 to approve Moderna's Flu vaccine this fall and for the first time ever it will be mRNA. We know the risks with mRNA having just seen that technology with Covid-19. Hit subscribe and never miss a show!

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare. In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This therapy focuses on Claudin18.2, marking an unprecedented expansion of CAR-T applications beyond hematologic malignancies. The significance of this breakthrough cannot be overstated, as it opens new avenues for treating cancers resistant to traditional therapies, offering hope to patients worldwide. Meanwhile, in regulatory news, the U.S. is closely examining Germany's proposed drug spending reforms due to concerns over "persistent underpayment" for new medications. This scrutiny highlights the complexities of international pharmaceutical pricing and could have profound implications for drug accessibility and pricing strategies across Europe. Sanofi is undergoing transformative changes under CEO Belen Garijo's leadership. The departure of R&D chief Houman Ashrafian and the appointment of Paulo Fontoura, known for his work at Roche, signal a strategic pivot to rejuvenate Sanofi's research and development pipeline. This move aims to address challenges within Sanofi's pipeline and inject new energy into its R&D initiatives. Reflecting broader industry trends, Eli Lilly is reevaluating its marketing strategies amid increasing emphasis on pharmaceuticals in mainstream health discussions. This introspection aligns with efforts across big pharma to enhance corporate image alongside product portfolios. The Federal Trade Commission recently mandated that Aurobindo divest four drugs as part of its $250 million acquisition of Lannett, addressing antitrust concerns and ensuring competitive balance in the generics market. Pfizer has made headlines with a rapid $10 billion oncology deal with Innovent Biologics. This collaboration underscores an industry trend towards swift, large-scale partnerships aimed at expanding global pharmaceutical ambitions. The deal's finalization in under five months illustrates the increasing pace at which such collaborations are being forged. Moderna continues to expand its mRNA capabilities beyond COVID-19 with unanimous FDA advisory committee support for its influenza vaccine candidate. This advancement signifies Moderna's strategic entry into broader vaccine markets, leveraging its mRNA platform to potentially transform vaccine development for seasonal influenza. AbbVie's acquisition of Apogee Therapeutics for $10.9 billion marks a competitive maneuver in the dermatology space. With a promising late-phase eczema drug candidate, AbbVie positions itself against market leaders like Eli Lilly, Regeneron, and Sanofi. Definium Therapeutics has announced promising phase 3 data for its novel LSD-based treatment for depression. This development has the potential to revolutionize mental health treatment paradigms by demonstrating unprecedented efficacy in psychedelic therapeutics. In an innovative stride forward, Insilico Medicine's collaboration with SK Biopharm on an AI-driven drug discovery initiative highlights the growing reliance on artificial intelligence to accelerate drug development pipelines. Targeting neuroimmune disorders, this partnership could be valued at over $2.5 billion, exemplifying AI's transformative potential in pharmaceutical innovation. These developments collectively highlight an industry characterized by rapid scientific advancements and strategic realignments. By expanding CAR-T therapies to solid tumors and integrating AI-driven drug discovery approaches, alongside significant regulatory updates and strategic collaborations, the pharmaceutical and biotech sectors are poised for continued evolution in patient care and drug development methodologies. As we continue to witness these transformative changes across pharmaceuticals and biotechnology, it remains crucial for stakeholders to adapt swiftly and collaborate effectively. The integration of novel technologies such as mRNA platforms, gene editing advancements, and AI-driven research will undoubtedly shape future healthcare outcomes and redefine traditional approaches to medicine. Thank you for tuning into Pharma Daily. We hope you found today's insights valuable as we navigate these dynamic shifts within the pharmaceutical and biotech landscapes together. Stay informed and join us next time as we continue to explore the cutting-edge developments driving healthcare innovation forward.Support the show

Dirige y presenta: Juan Carlos Baruque Hernández Sumario del programa DANIEL GARCÍA *¿Nos espían desde las tecnologías modernas? Nuestra Web: https://mundoinsolitoradio.es Contacta: +34 687 39 80 12 - Solo WhatsApp mundoinsolitoradio@hotmail.com Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Esta semana falamos do primeiro navio a vapor a atravessar o Atlântico, em 1819, e sobre as reuniões de Cortes em Portugal, entre os séculos XIII e XIX.Sugestões da semana:1. Eve MacDonald - Cartago - O Império que desafiou Roma. Bertrand, 2026.2. Olivier Aranda, Julien Guinand, Caroline Le Mao - Atlas das Guerras: Época Moderna. Guerra & Paz, 2026.-----Obrigado aos patronos do podcast:André Silva, Bruno Figueira, Cláudio Batista, Gustavo Fonseca, Isabel Yglesias de Oliveira, Joana Figueira, NBisme, Oliver Doerfler, Sara Esteves, Sofia Carvalho;Alexandre Carvalho, Andre Oliveira, Carlos Castro, Civiforum, Lda., Cláudia Conceição, Daniel Murta, Domingos Ferreira, Francisco C, Hugo Picciochi, Jorge Filipe, José Beleza, Luís André Agostinho, Miguel Cunha, Patrícia Gomes, Pedro Almada, Pedro Alves, Pedro Ferreira, Rui Roque, Tiago Pereira, Vera Costa;Adriana Vazão, Ana Gonçalves, André Abrantes, António Farelo, António J. R. Neto, Bruno Luis, Carlos Ribeiro, Carlos Ribeiro, Carolina Batista, Catarina Ferreira, Cláudia Brandão, César, Diogo Camoes, Diogo Freitas, Francisco Castro, Fábio Videira Santos, Gn, Goncalo Castro, GusRo, Hugo Palma, Hugo Vieira, Igor Silva, Joao Godinho, Joel José Ginga, Johnniedee, Jorge Manuel, João Barbosa, João Canto, João Carlos Braga Simões, João Diamantino, João Ferreira, João Félix, João Mendes, Liam Brockey, Luis Colaço, lvlheadwrecker, Mafalda Trindade, Marcos, Miguel Brito, Miguel Gama, Miguel Gonçalves Tomé, Miguel Oliveira, Miguel Salgado, Nuno Carvalho, Nuno Esteves, Nuno Moreira, Nuno Silva, Orlando Silva, Parte Cóccix, Paulo Guerreiro, Paulo Ramirez, Paulo Ruivo, Paulo Silva, Pedro Cardoso, Pedro Oliveira, Pedro Sebastião, Ricardo Pinho, Ricardo Santos, Rodrigo Candeias, Rui Magalhães, Rui Rodrigues, Simão, Simão Ribeiro, Thomas Ferreira, Tiago Matias, Tiago Sequeira, Tomás Matos Pires, Vitor Couto, Zé Teixeira.-----Ouve e gosta do podcast?Se quiser apoiar o Falando de História, contribuindo para a sua manutenção, pode fazê-lo via Patreon: https://patreon.com/falandodehistoria-----Música: "Hidden Agenda” de Kevin MacLeod (incompetech.com); Licensed under Creative Commons: By Attribution 4.0 License, http://creativecommons.org/licenses/by/4.0.Edição de Marco António.

Cap

Cap

Episode 2838 - In this wide-ranging Friday episode, Ted and Austin Broer connect ultra-processed food cardiovascular risk research, the FDA's surprise nine-to-zero approval of Moderna's RNA flu shot with only 26% efficacy, a daily multivitamin study showing reduced biological aging, speed limiter mandates coming to American cars by 2030, Apple's price hikes tied to AI data center memory costs, and foundational supplement guidance into a broadcast that delivers both urgent health warnings and sharp institutional accountability.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (6/19/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v79cuai","div":"rumble_v79cuai"}); Source Links (In Chronological Order): (14) CALL TO ACTIVISM on X: "This should frighten us all. REPORTER: What have you learned about not just the exercise of power but the limits on your power as a result of the conflict? TRUMP: There are no limits. REPORTER: No limits? TRUMP: No, I haven't learned that lesson yet. I know there are, but you https://t.co/oWD5JKxfAY" / X What The Hell Is Happening w/ Charlie Robinson (6/18/26) (6) TheTexasOne on X: "Blowing up drug boats saves American lives!" / X Top Pentagon Official Admits Boat Strike May Have Killed Victims of Human Trafficking (14) Drop Site on X: "⭕️ Senate threatens to freeze Hegseth's travel budget over Iran school bombing, boat strike videos Senate lawmakers are threatening to withhold 75 percent of Defense Secretary Pete Hegseth's travel budget if the Pentagon doesn't turn over more details on the deadly February https://t.co/5kK8Dg25v1" / X New Tab Animal Activists Arrested Attempting to Rescue Tortured Beagles While RFK Jr. Claims Ignorance Lawsuit Reveals "Cruel" Experiments on Kittens Continue Under Kennedy and Trump (9) The Last American Vagabond on X: "Neither side will do anything. People like Benny are the modern version of the Q psyop. They keep you feeling like you're just on the edge of massive change & disruption, all while making sure you never "counter-signal the leader" or ever actually do something. #ArrestSomeone" / X (10) The Last American Vagabond on X: "Prediction: no matter what you “reveal” no one will ever be arrested." / X (10) The Last American Vagabond on X: "This is what they mean when they say the “Epstein class”." / X (10) The Tennessee Holler on X: "This is real. A no-bid reflecting pool contract went to a sleazy Trump donor with a history of bribery and illegal loans. https://t.co/Ot5bJ4In4L https://t.co/hCDidnCC97" / X (10) The Last American Vagabond on X: "https://t.co/x99zqRZZyH" / X (10) The Last American Vagabond on X: "I don't think the team thought this one through. #GrandTheftAmerica" / X New Tab (12) The Last American Vagabond on X: "Trump's CDC just handed Pfizer over $1.2B for new COVID shots. Infant + adult. The big pharma machine never stopped. Full Segment: https://t.co/dLnl9a7jT6 Video by @JasonBassler1 https://t.co/uAvHoGjxSW" / X (12) Derrick Broze on X: "Is this MAHA? Moderna's MRNA Flu Vaccine Backed by FDA Advisers Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older. https://t.co/Uflt8rcSpM" / X Moderna's MRNA Flu Vaccine Backed by FDA Advisers Trial Details Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Briefing Document- FDA Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Briefing Document- FDA Israel's Election Manipulation Ignored, Over $1B To Pfizer For New COVID Shots & Trump's Iran Lies (12) Mary Talley Bowden MD on X: "This account was just suspended on @X for calling Pfizer a liar?" / X New Tab Trump's "Iran Deal" Is A Veiled Surrender and Retreat For The United States Trump declares Iran is 'FINISHED' amid reports Strait of Hormuz is closed again (15) The White House on X: "Iran is FINISHED. https://t.co/V9AXJ3VtTb" / X (15) RT on X: "DEPARTMENT OF WAR: ‘Give the enemy NIGHTMARES' COMMUNITY NOTE: ‘They gave the enemy $300 Billion instead' https://t.co/96q9utumkW https://t.co/tXAsb1Lvtb" / X (15) Seyed Mohammad Marandi on X: "The Zionists are massacring Lebanese families, while Trump confirms he'll keep Iran's frozen assets hostage. The Islamic Republic has proven that the Epstein Coalition is deceptive and untrustworthy. Their murderous and reckless policies will soon bring down the global economy. https://t.co/wQptsXR3i2" / X (15) Acyn on X: "Caputo: You had talked about you only wanted unconditional surrender. The MOU doesn't look like unconditional surrender. Trump: Well, it really probably is unconditional surrender. Caputo: It is? Trump: I think so. https://t.co/A3JENjaXES" / X (19) The Last American Vagabond on X: "This is just sad. You always know it's an obvious win, when they have to walk you through WHY it's a win, let alone use abstract and undefinable claims as reference points, and use achievements that were the status quo before the war was started. #WINNING" / X New Tab (19) The Kobeissi Letter on X: "BREAKING: Iran officially posts the fully executed “Memorandum of Understanding” which has now taken effect. https://t.co/LteFvqqL9v" / X U.S.-Iran deal: Read the full text (19) Aaron Rupar on X: "Q: They are being allowed to sell oil without making concrete nuclear commitments. How is that not lopsided? JD VANCE: They've made very concrete nuclear commitments. They have committed to the destruction of their highly enriched stockpile. https://t.co/vsJ3ZVeAt9" / X (19) Ryan Rozbiani on X: "I just realized, almost EVERYTHING the Iranian negotiation team told us about this deal from the first day of the ceasefire turned out TRUE Everything Trump told us he would do, he CONCEDED on. Iran even gets to KEEP their Nuclear Program for civilian purposed. Even TRUMP https://t.co/BPt49yC4R5" / X New Tab (19) Ambassador Mike Huckabee on X: "Fortunately @SecRubio made clear that Iran & Hezbollah aren't linked in a deal. @Israel doesn't need Iran permission to defend itself. The tether of terror must end." / X (19) The White House on X: ""The United States is committed to PEACE... We expect a complete Ceasefire on all fronts, including Lebanon, Hezbollah, and Israel." - President Donald J. Trump

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this interview I talked with the Senator from Wisconsin, Ron Johnson. We discussed his bombshell report called, Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals. In this report, Senator Johnson and his team reveals that many people within the FDA and HHS, among other governmental organizations, knew that the COVID-19 vaccines were linked to strokes and even death as early as 2021. Senator Johnson's team found conclusive evidence that the United States Government, the majority of American media companies, and the monopolistic Pharmaceutical Companies worked together to suppress the truth about the Vaccines and, in turn, killed thousands of innocent American citizens. For being one of the most significant reports in modern history, you would think that this story would be on the front page of every major news network and newspaper in America – you would be wrong. Senator Johnson sent his own Op-Ed regarding this report to The New York Times, The Wall Street Journal, USA Today, and many other publications and, to nobodies surprise, he was turned down for publication. We think this had something to do with the fact that many, if not all, of these news companies are sponsored by Pfizer or Moderna and would rather keep in good standing with their financiers than tell the American people the truth about what happened during the COVID-19 Pandemic. We, at The Paradox Press, are not beholden to the Medical Mafia and for that reason, we have the ability to tell the truth. I hope you enjoy. BUY DR MARY TALLEY BOWDEN'S BOOK Go subscribe to The Paradox Press now!Follow me on X: https://x.com/andyschmitt99

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über Zweifel am Debasement Trade, die große Biontech-Debatte, und die Hausse des Gebrauchtwagenhändlers Auto1. Außerdem geht es um SpaceX, Moderna, BioNTech, AMD, Arm, Broadcom, Intel, Micron, Apple, Auto1, Kroger, BMW, Volkswagen, Mercedes-Benz, Tesla, BYD, SAIC, Commerzbank, Goldman Sachs. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Sabemos la responsabilidad que implica traer un hijo al mundo, o tal vez hacerse cargo de una mascota. Por eso las parejas modernas están optando por no tener responsabilidades y gastarse su dinero en viajes y placer. Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

On this, our 325th Evolutionary Lens livestream, we discuss Hanta virus and drought. First: what is the natural history of Hantavirus, do any Hantaviruses transmit directly from human to human, and what is going on with the M.V. Hondius, the cruise ship on which Hantavirus has made a stand? Given its mechanisms of action, Ivermectin is likely to treat Hantavirus (a negative sense single-stranded RNA virus), but the WHO dismisses the possibility. Moderna is working on a Hantavirus vaccine, even though the Number Needed to Treat is sky high. What is going on? Then: in Washington state, we're experiencing a very wet drought. The Department of Ecology has declared a drought (again), and the snow pack is low, but all other indicators—from rivers to reservoirs to soil moisture—are excellent. Cliff Mass, atmospheric scientist, puts the evidence in one place and calls bull on the drought diagnosis.*****Our sponsors:Xlear: Xylitol nasal spray that acts as prophylaxis against respiratory illnesses by reducing the stickiness of bacteria and viruses. Find Xlear online, or at your local pharmacy, grocery store, or natural products store.Fresh Pressed Olive Oil Club: Freshly harvested and delicious. Go to http://www.GetFreshDarkHorse.com to get a bottle of the best olive oil you've ever had for $1 shipping.CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Hantavirus and the elders: https://asm.org/articles/2024/october/indigenous-knowledge-solved-mysterious-outbreakToledo et al 2022. Evidence for human-to-human transmission of hantavirus: a systematic review. The Journal of infectious diseases, 226(8): 1362-1371: https://academic.oup.com/jid/article/226/8/1362/6369311Zaidi & Dehgani-Mobaraki 2022. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. The Journal of antibiotics, 75(2): 60-71: https://www.nature.com/articles/s41429-021-00491-6The WHO on the recent outbreak: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON599Cliff Mass – There is no drought emergency: https://cliffmass.blogspot.com/2026/05/the-is-no-drought-emergency-in.htmlStatewide drought declared in WA: https://ecology.wa.gov/about-us/who-we-are/news/2026/april-8-statewide-drought-declared-due-to-dismal-snowpackSupport the show